Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 11/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204710 | 0.95 | ALDH1A1 (0.73) | SIRT6ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL3641803 | 0.93 | SIRT6 (0.63) | SIRT6ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL310163 | 0.89 | ALDH1A1 (0.60) | SIRT6ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL520015 | 0.84 | SIRT6 (1.00) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL519977 | 0.84 | ALDH1A1 (0.60) | SIRT6ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL6367942 | 0.84 | ALDH1A1 (1.00) | SIRT6ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL29788578 | 0.84 | ALDH1A1 (1.00) | SIRT6ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL23654648 | 0.83 | SIRT6 (0.78) | SIRT6ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL13395160 | 0.83 | SIRT6 (0.78) | SIRT6ALDH1A1LMNAMAPTHTT | |
| SCHEMBL29800124 | 0.82 | ALDH1A1 (0.97) | SIRT6ALDH1A1LMNAMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| CN-106905245-B | 2, 4-disubstituted pyrimidines | 正大天晴药业集团股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-19 | — | — | US | disclosed |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | BUB1B, BUB1, CDK1 | SIRT6 3693/4885ALDH1A1 4006/4885LMNA 1312/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | SIRT6 3640/4885ALDH1A1 3742/4885LMNA 1306/4885 |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | SIRT6 1497/4885ALDH1A1 3410/4885LMNA 2828/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | SIRT6 3640/4885ALDH1A1 3742/4885LMNA 1306/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | SIRT6 3640/4885ALDH1A1 3742/4885LMNA 1306/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | SIRT6 1461/4885ALDH1A1 378/4885LMNA 4161/4885 |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | SIRT6 3640/4885ALDH1A1 3742/4885LMNA 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.